This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|April 1, 2011
Improve the Performance and Lower the Costs of ODT Drug Applications
J.T.Baker® PanExcea™ MC200G performance excipient from Avantor™ Performance Materials (formerly Mallinckrodt Baker) is engineered to reduce your cost-per-tablet.
Advertisement
J.T.Baker® PanExcea MC200G performance excipient from Avantor Performance Materials (formerly Mallinckrodt Baker) is an orally disintegrating tablet (ODT) building block enabling formulators to develop a direct compression ODT that disintegrates rapidly while offering good taste and texture. PanExcea™ MC200G offers a unique, dense spherical particle shape and morphology to maximize API loading capacity, blend flowability and taste-masking.
An excipient-based solution, PanExcea MC200G is also engineered to reduce cost-per-tablet because it can be produced using standard manufacturing and packaging equipment. This reduces or eliminates the costs of ODT technology licensing and new equipment investment.
Learn more:
Avantor Performance Materials
222 Red School Lane
Phillipsburg, NJ 08865
1-855-AVANTOR (within U.S.)
1-908-859-2151 (outside U.S.)
Fax: 908-859-6905
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement